Investor Ideas, Trading Ideas and Stocks to Watch

Friday, September 18, 2020

#AIEye Episode 435: GBT Technologies (OTCPK: $GTCH) Updating Epsilon IC Program for Advanced Manufacturing Nodes and BrainChip (ASX: BRN.AX) Validates Akida NSoC

#AIEye Episode 435: GBT Technologies (OTCPK: $GTCH) Updating Epsilon IC Program for Advanced Manufacturing Nodes and BrainChip (ASX: BRN.AX) Validates Akida NSoC

Global #AI in #Fintech Market to Reach $9.125 Billion by 2027

Point Roberts WA, Vancouver BC – September 18, 2020 – Investorideas.com (www.investorideas.com), a global investor news source covering Artificial Intelligence (AI) brings you today’s edition of The AI Eye- watching stock news, deal tracker and advancements in artificial intelligence.

Listen to today’s podcast:

https://www.investorideas.com/Audio/Podcasts/2020/091820-AI-Eye.mp3

Read this in full

https://www.investorideas.com/news/2020/artificial-intelligence/09181AIEye-GBT-BrainChip.asp

Hear the Ai Eye on Spotify

Today’s Column- The AI Eye- Watching stock news, deal tracker and advancements in artificial intelligence

Stocks discussed: (OTCPINK:GTCH) (ASX:BRN)

GBT Technologies Inc. (OTCPINK:GTCH) along with its joint venture partner, Alpha EDA, LLC, is “in the process of updating its Epsilon, IC (integrated circuit) reliability clean-by-construction program, preparing for advanced manufacturing nodes.” GBT’s CTO Danny Rittman explained:

"Alpha and the Company took a decision that involves implementation of a new technology phenomenon, making our Epsilon reliability program capable of providing accurate analysis and correction. Alpha and the Company are implementing new algorithms and flows which we believe is an evolutionary step from the traditional FinFets [Fin Field-Effect Transistors]. This upcoming node will create major design challenges, yet it will provide significant higher performance, and lower power consumption. These are critical when it comes to advanced ICs. The new transistors will be more difficult to make, expensive, and the migration will be painful, but it'll be worth it. This will enable putting more devices on silicon, consuming less power and with much higher performance. Together, we are now planning to update our Epsilon software, ensuring on-the-fly reliability checks for upcoming future microchips. With these upcoming processes Alpha will have to take into account new physics challenges and phenomena in order to make these chips reliable and working at optimal conditions. Alpha plans to implement the Company’s machine learning technology as a key factor to study and analyze circuitries including their weak spots, taking into account physics aspects. Epsilon is expected to provide reliability alerts and corrections suggestions, early during the design phase. The Company’s AI engine will be trained with new reliability models, adapting to advanced processes, based on physics-of-failure mechanisms. It is intended to identify weak thermal spots, predicting potential reliability failures, check for Electromigration (EM), Self heat and voltage (IR) Drop phenomenon, providing the ultimate reliability-aware IC design environment. We believe in early design stage reliability analysis and predictions, early addressing and auto-correction, which will become a key player when designing modern chips, especially with the upcoming 5nm and 3nm manufacturing processes. In these nodes, chips can overheat, perform poorly or fail and manufacturers will need to be well prepared; the sooner, the better."

BrainChip Holdings Ltd (ASX:BRN) has validated its Akida Neuromorphic System-on-Chip (NSoC) design with functional silicon. BrainChip CEO Louis DiNardo explained:

"We have validated the functionality of the Akida silicon and performed significant testing. The devices received from the MPW will provide engineering samples and evaluation boards for our early access customers. Now our focus is on continued development of software and firmware drivers. We expect to produce a production mask set in the fourth quarter of 2020 and then move forward with volume production wafer fabrication, assembly and test operations. The BrainChip team is very proud of this significant achievement and milestone in our quest to introduce Akida and achieve commercial success with a revolutionary product that solves the real-world challenges of implementing artificial intelligence at the Edge."

Global AI in Fintech Market to Reach $9.125 Billion by 2027

A report published by Data Bridge Market Research finds that the global AI in Fintech market will reach $9.125 billion by 2027 with a compound annual growth rate (CAGR) of 65.7 percent in the forecast period 2020-2027. An excerpt from the report description outlines trends in the market’s growth:

Process automation within financial organizations is enhancing the market growth [as] artificial intelligence can perform even more complex automation processes.

Fintech is one of the fastest growing industries [in the world] owing [to] the penetration of internet users. Users are briskly moving to mobile devices to perform transactions, [thereby] growing [the] internet user base. As this will [increase risk] of cyber-attacks from fraud [leading to] the incorporation of artificial intelligence [gaining] growth over the forecast period. Increasing use of AI-enabled technologies solutions in the capital market is an opportunity for the AI in fintech market.

Sam Mowers, Investorideas.com

Read and hear other editions of the AI Eye

For a list of artificial intelligence stocks on Investorideas.com visit here or become an Investor Ideas member

About Investorideas.com - News that Inspires Big Investing Ideas Investorideas.com is a recognized news source publishing third party news, research and original financial content. Learn about investing in stocks and sector trends with our news alerts, articles, podcasts and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy and more. Investor Idea’s original branded content includes the following podcasts and columns : Crypto Corner , Play by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column, Cleantech and Climate Change , Exploring Mining the AI Eye .

The Investorideas.com podcasts are also available on iTunes, Spotify, Tunein, Stitcher, Spreaker.com, iHeartRadio and Google Play Music.

Visit the Podcast page at Investorideas.com:

https://www.investorideas.com/Audio/

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. Disclosure: GTCH is a paid annual news and social media client on Investorideas.com More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

The AI Eye- Watching stock news, deal tracker and advancements in artificial intelligence is an original content brand of Investorideas.com

Download our Mobile App for iPhone and Android

Join our Investor Club https://www.investorideas.com/membership/

Contact Investorideas.com

800 665 0411

Get more Technology stock investor ideas - news, articles, podcasts and stock directories

#Cannabis #Stock news - Cannabis Suisse (OTC: $CSUI) Reports New Service "Your Cannabis Grow" to the European Market; @SuisseCorp

#Cannabis #Stock news - Cannabis Suisse (OTC: $CSUI) Reports New Service "Your Cannabis Grow" to the European Market; @SuisseCorp

DIETIKON, SWITZERLAND, September 18, 2020 - ( Investorideas.com newswire) – cannabis stock news - Cannabis Suisse (OTC: CSUI),recently reported a new service to the European market, Your Cannabis Grow, an innovative service which allows customers from Europe to grow their own cannabis seedling in one of Cannabis Suisse's indoor farms located in Switzerland.

Read this news featuring CSUI in full at https://www.investorideas.com/CO/CSUI/news/2020/09181Your-Cannabis-Grow-European-Market.asp

This is an ethical, transparent and sustainable way to source the product containing essential CBD and EU sanctioned levels of THC - individually cultivated straight from the farm. Cannabis Suisse experts will monitor the entire cultivation process daily.

Customers can choose from an array of different cannabis strains. All the customers will be provided with a live video where they can watch the growth of the plants from the first seeding till the final harvest. The entire growth cycle of a cannabis plant is approximately 8-10 weeks, drying time is between 7-13 days. After being harvested, the THC level within the weed needs to be adjusted to meet the legal criteria of the country where the customer resides, then customers can have their weed shipped directly to their home. Harvest result is usually between 20 and 35 gr. per plant. On site, the plants are taken care of by Cannabis Suisse's master growers that are also involved in manufacturing of all the other products.

The price of 120 CHF includes all these services. Cannabis Suisse clients get a clone, a nameplate, a weekly photo of the plant, a certificate of the plant owner, photos of their drying plate, and as a result flowerheads shipped from the farm in anonymous packages.

The product can be ordered from the special website of the Company and from selected resellers. Cannabis Suisse Corp. also plans to sell it via a network of kiosks where customers can buy a plastic card already containing login and password data for the website. The intention is to do it especially in those type of kiosks that identify themselves as tobacco shops. Buying a card, customers are always sure that there is free space available at the farm.

In connection with the expansion of its services, Cannabis Suisse Corp. announces many special offers for its customers. There is giving out of 10 plants only for the subscribing to the Company's newsletters. As well ordering three plants at once, a buyer will receive the fourth one as a gift. Cannabis Suisse Corp. also offers open days. On selected days, the growers will be happy to welcome their customers personally at the facility.

Your Cannabis Grow is a hassle-free way to grow your own weed, there are many benefits and saving money is not the only one. Growing own cannabis plant has never been easier if the plant is in the hands of Cannabis Suisse's master growers. Cannabis Suisse has a top tier indoor farm that has no contaminants, customers' plants will be cared the same way as the rest of the products and receive the optimal conditions to grow and flourish. Growing own hemp is tricky even if it is grown only during the summer when there is not any need for special equipment.

Your Cannabis Grow is a service for everyone, but savvy customers that are well-versed in the different kinds of strains and already know what they prefer for regular consumption are going to see this service as an essential one. For someone who is experimenting, looking for new flavors or maybe new to cannabis consumption, Your Cannabis Grow might not be a commitment that is worth taking just yet. However, once a client has found that special strain, Your Cannabis Grow is a certain way to make sure that the strain is always in stock and even cheaper than ready-made products.

At the moment, a customer can choose from 6 different cannabis strains that give different aroma, taste and experiences. They are V1, Harlequin, White Alpine, Limoncello, Orange Alpine, Strawberry. This a great selection at launch and is going to be expanded and improved in the future.

Growing medical marijuana is legal in some European countries, but in Switzerland it is allowed to grow and sell cannabis for recreational or commercial use. It makes Switzerland unique and gives some interesting benefits for companies such as Cannabis Suisse Corp. Cannabis Suisse is using this opportunity to create a new market while also benefiting customers with a chance to own a legal cannabis farm plant that definitely has more benefits than having one in a back yard.

Cannabis Suisse Corp. is a forward-looking company and understands that consistent quality, trust and community creates a strong brand. The Company creates innovate products that people need and want to buy. Your Cannabis Grow is a service that is hopefully going to create a community that will trust in Cannabis Suisse future products and believe them to be worth sharing and supporting.

The release of Your Cannabis Grow is a new step for Cannabis Suisse Corp., while being extremely beneficial to customers. The service requires a time investment, but the outcome and saving are definitely worth the waiting. The service will evolve in the future and could even become an industry standard.

ABOUT CANNABIS SUISSE CORP.

Cannabis Suisse Corp. is a fully licensed cannabis cultivation and distribution company in Switzerland, for recreational tobacco products and medical CBD oils. The Company's facilities for producing cannabis are based in Dietikon, Switzerland, and contain the art surveillance equipment to enable an around the clock webcast. Cannabis Suisse grows high quality, organic cannabis with sustainable, all-natural principles. The Company's products are laboratory tested to ensure the end users have access to a standardized, safe and consistent product. Cannabis Suisse proprietary trademarked MoldStandard is a quantitative microbiology method for analyzing yeast and mold counts in harvested cannabis plants. Cannabis Suisse proprietary trademarked CannaMec is a method for quantifying and removing residual solvents during packaging and storage of CBD products. Cannabis Suisse Corp. currently sells via a distribution network of Swiss retailers and online shops, under the retail brand Alpine Cannabis.

FORWARD-LOOKING DISCLAIMER

This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Cannabis Suisse Corp. to be materially different from the statements made herein.

CONTACT:

Alain Parrik

Cannabis Suisse Corp.

+41445865314

alain.parrik@cannabissuisse.biz

SOURCE: Cannabis Suisse Corp

Cannabis Suisse (OTC: CSUI) is a featured Cannabis stock on Investorideas.com

Visit profile page

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions.

Disclosure : Cannabis Suisse Corp. (OTC: CSUI) is a paid monthly cannabis company on Investorideas.com ( five thousand per month) More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell cannabis products.

Get more Cannabis Stock Investor Ideas - news, articles, podcasts and stock directories

Buy a cannabis guest post on Investorideas.com

#CryptoCorner #Podcast Episode 452: Hut 8 (TSX: $HUT.TO) Receives New Equipment, and Wirex Announces Multicurrency Card Launch with Support from Mastercard (NYSE: $MA), Libra Association (NasdaqGS: $FB) Welcomes #Blockchain Capital as Member and Appoints Former HSBC (NYSE: $HSBC) CEO

#CryptoCorner #Podcast Episode 452: Hut 8 (TSX: $HUT.TO) Receives New Equipment, and Wirex Announces Multicurrency Card Launch with Support from Mastercard (NYSE: $MA), Libra Association (NasdaqGS: $FB) Welcomes #Blockchain Capital as Member and Appoints Former HSBC (NYSE: $HSBC) CEO

Point Roberts, WA, Delta BC September 18, 2020 - Investorideas.com, a leader in crypto and blockchain investing news brings you today’s edition of the Crypto Corner podcast and commentary on what’s driving cryptocurrency stocks and the crypto market.

Listen to today’s Crypto Corner Podcast:

https://www.investorideas.com/Audio/Podcasts/2020/091820-CryptoMarket.mp3

Read this in full at https://www.investorideas.com/news/2020/crypto-corner/09181HUT8-Wirex-MasterCard.asp

Get the Crypto Corner Podcast on iTunes

Get the Crypto corner on Spotify

Stocks discussed: (NasdaqGS:FB) (NYSE:HSBC) (TSX:HUT) (NYSE:MA)

The Libra Association, an independent member organization for Facebook’s (NasdaqGS:FB) Libra project, welcomed crypto investment firm Blockchain Capital as its newest member today. Dante Disparte, Vice Chairman and head of policy and communications for the Libra Association, commented:

"As a member of the Libra Association, Blockchain Capital brings deep industry insight and a dynamic network of supporters as we work on building a blockchain-based payment system that supports responsible financial services innovation.”

Yesterday, the Libra Association announced that it had appointed James Emmett as the Managing Director of its operating company subsidiary, Libra Networks LLC. Emmett, who previously served as CEO of banking giant HSBC (NYSE:HSBC), commented:

“As someone who is passionate about the opportunities for financial services and technology to make a real difference, I am delighted to be joining Libra Networks with a mission to enhance financial innovation and inclusion and to deliver the operationalization of the network.”

Hut 8 Mining Corp. (TSX:HUT) has received its planned 1,000 M31S and 1,000 M31S+ machines on-site at its Medicine Hat facility, which together will have an output of 154 PH/s using approximately 6.7MW of power. Jimmy Vaiopoulos, the company’s Interim CEO, said:

"With the recent press releases over the last six weeks including this new equipment being installed, the transfer of Clarke chips to Medicine Hat completed, and the transfer of management of both sites finalized, Hut 8 has increased its hash rate while lowering its cost to mine bitcoin, thereby strengthening its gross mining margins. Every dollar and bitcoin counts in the mining sector as we continue to upgrade our ASIC chips and strive to be one of the industry's lowest cost miners."

Crypto payments platform Wirex has announced the launch of its new multicurrency Wirex Card, supported by Mastercard (NYSE:MA). According to the press release, the card will be “linked to 19 secure crypto and traditional currency accounts in the Wirex app,” allowing cardholders to “seamlessly spend multiple fiat and cryptocurrencies in day-to-day life without exchanging or offboarding.”

Sam Mowers, Investorideas

For investors following the sector Investor Ideas has a comprehensive Bitcoin, Blockchain and Digital Currency Stocks Directory

The Crypto Corner is part of the Investor Ideas Membership content

The Investorideas.com podcasts are also available on iTunes, Spotify, Tunein, Stitcher, Spreaker.com, iHeartRadio and Google Play Music.

Visit the Podcast page at Investorideas.com: https://www.investorideas.com/Audio/

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

Cryptocurrency Disclaimer

Investorideas.com news content is not meant to be a solicitation to buy or sell cryptocurrencies and Investorideas.com does not directly sell cryptocurrencies; but acts as a news and research resource for interested investors following the blockchain sector.

Download our Mobile App for iPhone and Android

Join our Investor Club https://www.investorideas.com/membership/

Contact Investorideas.com

800-665-0411

Get more Bitcoin and Blockchain Investor ideas – news, articles, podcasts and stock directories

Investor Ideas Adds New Biotech (Nasdaq: $ACER) (Nasdaq: $AIKI) (Nasdaq: $JAN) (TSXV: $MDP.V) and Gaming/eSport Stocks (Nasdaq: $SLGG)

Investor Ideas Adds New Biotech (Nasdaq: $ACER) (Nasdaq: $AIKI) (Nasdaq: $JAN) (TSXV: $MDP.V) and Gaming/eSport Stocks (Nasdaq: $SLGG)

Point Roberts WA, Delta BC, September 18, 2020 – (Investorideas.com Newswire) Investorideas.com, a global news source and leading retail investor resource announces its weekly roundup of stocks added to its free global stock directories; biotech, gaming and eSport.

Read this news in full at https://www.investorideas.com/news/2020/main/09181Stocks.asp

The newest biotech companies are involved in a variety of pharmaceutical and medical device products as well as life sciences and healthcare products and services, including some related to Coronavirus (COVID-19).

The latest gaming/eSport companies include a leading gaming community and content platform and the latest gaming indice - MVIS Global Video Gaming & eSports (AUD) Index (MVESPOA).

New stocks added to Biotech stocks directory

Acer Therapeutics (NasdaqGS:ACER) is a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs. Acer’s pipeline includes four clinical-stage candidates: emetine hydrochloride for the treatment of patients with COVID-19; ACER-001 (a taste-masked, immediate release formulation of sodium phenylbutyrate) for the treatment of various inborn errors of metabolism, including urea cycle disorders (UCDs) and Maple Syrup Urine Disease (MSUD); EDSIVO™ (celiprolol) for the treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation; and osanetant for the treatment of induced Vasomotor Symptoms (iVMS). Each of Acer’s product candidates is believed to present a comparatively de-risked profile, having one or more of a favorable safety profile, clinical proof-of-concept data, mechanistic differentiation and/or accelerated paths for development through specific programs and procedures established by the FDA.

AIkido Pharma Inc. (NasdaqGS:AIKI) was initially formed in 1967 and is a biotechnology company with a diverse portfolio of small-molecule anti-cancer therapeutics. The Company's platform consists of patented technology from leading universities and researchers and we are currently in the process of developing an innovative therapeutic drug platform through strong partnerships with world renowned educational institutions, including The University of Texas at Austin and Wake Forest University. Our diverse pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). In addition, we are constantly seeking to grow our pipeline to treat unmet medical needs in oncology. The Company is also developing a broad spectrum antiviral platform that may potentially inhibit replication of multiple viruses including Influenza virus, SARS-CoV (coronavirus), MERS-CoV, Ebolavirus and Marburg virus.

Annovis Bio (NYSE American:ANVS) Headquartered in Berwyn, Pennsylvania, Annovis Bio, Inc. (Annovis) is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and Alzheimer’s in Down Syndrome (AD-DS). We believe that we are the only company developing a drug for AD, PD and AD-DS that inhibits more than one neurotoxic protein and, thereby, improves the information highway of the nerve cell, known as axonal transport. When this information flow is impaired, the nerve cell gets sick and dies. We expect our treatment to improve memory loss and dementia associated with AD and AD-DS, as well as body and brain function in PD. We have an ongoing Phase 2a study in AD patients and have commenced a second Phase 2a study in AD and PD patients.

Aptorum Group Limited (NasdaqGM:APM) is a pharmaceutical company dedicated to the discovery, development and commercializing of therapeutic assets to treat diseases with unmet medical needs, particularly infectious diseases and cancers (including orphan oncology indications). The pipeline of Aptorum is also enriched through the establishment of drug discovery platforms that enable the discovery of new therapeutics assets through, e.g. systematic screening of existing approved drug molecules, and microbiome-based research platform for treatments of metabolic diseases. In addition to the above main focus, we are also pursuing therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women’s health and other disease areas. We also have projects focused on surgical robotics and natural supplement for women undergoing menopause and experiencing related symptoms.

Arcturus Therapeutics (NasdaqGM:ARCT) ounded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a clinical-stage mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR™ mRNA Technology and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus’ diverse pipeline of RNA therapeutic and vaccine candidates includes self-replicating mRNA vaccine programs for SARS-CoV-2 (COVID-19) and Influenza, and other programs to potentially treat Ornithine Transcarbamylase (OTC) Deficiency, Cystic Fibrosis, Cardiovascular Disease along with partnered programs including Glycogen Storage Disease Type 3, Hepatitis B Virus, and non-alcoholic steatohepatitis (NASH). Arcturus’ versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, replicon RNA, antisense RNA, microRNA, DNA, and gene editing therapeutics. Arcturus’ technologies are covered by its extensive patent portfolio (192 patents and patent applications, issued in the U.S., Europe, Japan, China and other countries). Arcturus’ commitment to the development of novel RNA therapeutics has led to collaborations with Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, Ultragenyx Pharmaceutical, Inc., Takeda Pharmaceutical Company Limited, CureVac AG, Synthetic Genomics Inc., Duke-NUS, and the Cystic Fibrosis Foundation

Artelo Biosciences, Inc. (NasdaqGS:ARTL) is a San Diego-based biopharmaceutical company dedicated to the development and commercialization of proprietary therapeutics targeting the endocannabinoid system and related pathways. Artelo is rapidly advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, pain, and inflammation. Led by proven biopharmaceutical executives collaborating with highly respected researchers and technology experts, the company applies leading edge scientific, regulatory, and commercial discipline to develop high-impact therapies.

JanOne Inc. (NasdaqGS:JAN) is focused on developing treatments for diseases that cause severe pain. By alleviating pain at the source, JanOne aims to reduce the need for opioid prescriptions to treat disease associated pain that can lead to opioid abuse. The company is also exploring solutions for non-addictive pain medications. Its lead candidate JAN101 is for treating peripheral artery disease (PAD), a condition that affects over 8.5 million Americans. JAN101 demonstrated positive results in a Phase 2a clinical trial, and Phase 2b trials are expected to begin in early 2021. JanOne is dedicated to funding resources toward innovation, technology, and education for PAD, associated vascular conditions and neuropathic pain. JanOne continues to operate its legacy businesses under their current brand names, which are undergoing review to determine appropriate strategic alternatives.

Medexus Pharmaceuticals Inc. (TSX:MDP.V) is a leading specialty pharmaceutical company with a strong North American commercial platform. The Company’s vision is to provide the best healthcare products to healthcare professionals and patients, through our core values of Quality, Innovation, Customer Service and Teamwork. Medexus Pharmaceuticals is focused on the therapeutic areas of auto-immune disease, hematology and allergy. The Company’s leading products are: Rasuvo™ and Metoject®, a unique formulation of methotrexate (auto-pen and pre-filled syringe) designed to treat rheumatoid arthritis and other auto-immune diseases; IXINITY®, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with Hemophilia B – a hereditary bleeding disorder characterized by a deficiency of clotting factor IX in the blood, which is necessary to control bleeding; and Rupall®, an innovative allergy medication with a unique mode of action.

American Shared Hospital Services (NYSE American:AMS) provides turnkey technology solutions for advanced radiosurgical and radiation therapy services. AMS is a world leader in providing Gamma Knife radiosurgery equipment, a non-invasive treatment for malignant and benign brain tumors, vascular malformations, and trigeminal neuralgia (facial pain). The Company also offers proton therapy, and the latest IGRT, IMRT and MR/LINAC systems.

Zynex, Inc. (NasdaqGS:ZYXI) founded in 1996, markets and sells its own design of electrotherapy medical devices used for pain management and rehabilitation; and the Company's proprietary NeuroMove device designed to help recovery of stroke and spinal cord injury patients. Zynex is also developing a new blood volume monitor for use in hospitals and surgery centers.

New stocks added to Gaming/eSports stocks directory

MVIS Global Video Gaming & eSports (AUD) Index (MVESPOA) is a pure play index that tracks the performance of global companies that generate at least 50% of their revenues (25% for current components) from the video gaming and eSports sector. These companies may include those that develop video games and related software/hardware, streaming services, and are involved in eSports events.

Super League Gaming (NasdaqGS:SLGG) is a leading gaming community and content platform that gives everyday gamers multiple ways to connect and engage with others while enjoying the video games they love. Powered by patented, proprietary technology systems, Super League offers players the ability to create gameplay-driven experiences they can share with friends, the opportunity to watch live streaming broadcasts and gameplay highlights across digital and social channels, and the chance to compete in events and challenges designed to celebrate victories and achievements across multiple skill levels. With gameplay and content offerings featuring more than a dozen of the top video game titles in the world, Super League is building a broadly inclusive, global brand at the intersection of gaming, experiences and entertainment. Whether to access its expanding direct audience or the company’s unique content production and virtual event capabilities, third parties ranging from consumer brands, video game publishers, television companies, traditional sports organizations, concert promoters, and more, are turning to Super League to provide integrated solutions that drive business growth.

The directories are not meant as recommendations but as a research tool to discover opportunities and trading ideas in a particular sector.

About Investorideas.com - News that Inspires Big Investing Ideas Investorideas.com is a recognized news source publishing third party news and press releases, research and our own original financial content. We were one of the first retail investor sites to cover renewable energy and cleantech stocks at investorideas.com and our domain Renewableenergystocks.com. We were also one of the most well- known and cited defense stock sites, featuring our domain Homelanddefensestocks.com at its peak.

We follow the money for investors as sector sentiment shifts and technology disrupts. Our mission is to provide investor ideas with breaking news, resources, industry articles and interviews with leading experts.

Learn about investing in stocks and sector trends with our news alerts, articles, podcasts and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy and more. Investor Idea's original branded content includes the following podcasts and columns: Crypto Corner, Play by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column, Cleantech and Climate Change, Exploring Mining and the AI Eye.

Public companies within the sectors we cover use our news and content services to tell their story to interested investors. Paid for content is disclosed.

More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

Learn more about our news, PR and social media services at Investorideas.com

https://www.investorideas.com/Investors/Services.asp

Download our Mobile App for iPhone and Android

Join our Investor Club https://www.investorideas.com/membership/

Contact Investorideas.com

800 665 0411

About Investorideas.com

About Investorideas.com - Big Investing Ideas Investorideas.com is a platform for investing ideas. We publish breaking stock news, stock research, guest posts and create original top rated investing podcasts, plus sector tag articles featuring up and coming companies and industry leaders. Investor Idea’s original branded content includes the Crypto Corner Podcast , Play by Play Sports Podcast , Cannabis News and Stocks on the Move Podcast , Cleantech and Climate Change Podcast, Exploring Mining Podcast , Betting on Gaming Stocks Podcast and the AI Eye Podcast. We also create free investor stock directories for AI and tech, biotech, cannabis, cleantech, crypto, defense, gaming, health and wellness, mining, oil and gas, sports and water. Public companies within the sectors we cover can use our news publishing and content creation services to help tell their story to interested investors. Public companies within the sectors we cover use our news and content services to tell their story to interested investors. Paid for content is disclosed.

Disclaimer/disclosure

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

Investor Ideas, Trading Ideas and Stocks to Watch

Friday, September 18, 2020

#AIEye Episode 435: GBT Technologies (OTCPK: $GTCH) Updating Epsilon IC Program for Advanced Manufacturing Nodes and BrainChip (ASX: BRN.AX) Validates Akida NSoC

#Cannabis #Stock news - Cannabis Suisse (OTC: $CSUI) Reports New Service "Your Cannabis Grow" to the European Market; @SuisseCorp

#CryptoCorner #Podcast Episode 452: Hut 8 (TSX: $HUT.TO) Receives New Equipment, and Wirex Announces Multicurrency Card Launch with Support from Mastercard (NYSE: $MA), Libra Association (NasdaqGS: $FB) Welcomes #Blockchain Capital as Member and Appoints Former HSBC (NYSE: $HSBC) CEO

Investor Ideas Adds New Biotech (Nasdaq: $ACER) (Nasdaq: $AIKI) (Nasdaq: $JAN) (TSXV: $MDP.V) and Gaming/eSport Stocks (Nasdaq: $SLGG)

Blog Archive

Links

Search This Blog